Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Return on Equity (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Return on Equity for 6 consecutive years, with 0.47% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity fell 5.0% to 0.47% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.47%, a 5.0% decrease, with the full-year FY2025 number at 0.41%, up 3.0% from a year prior.
  • Return on Equity was 0.47% for Q4 2025 at Relay Therapeutics, down from 0.47% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.09% in Q1 2021 to a low of 0.5% in Q4 2021.
  • A 5-year average of 0.4% and a median of 0.44% in 2021 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: crashed -42bps in 2021, then increased 20bps in 2022.
  • Relay Therapeutics' Return on Equity stood at 0.5% in 2021, then surged by 40bps to 0.3% in 2022, then crashed by -50bps to 0.45% in 2023, then grew by 7bps to 0.42% in 2024, then decreased by -12bps to 0.47% in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Return on Equity are 0.47% (Q4 2025), 0.47% (Q3 2025), and 0.45% (Q2 2025).